Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elan, Wyeth’s Bapineuzumab Data Mixed In Phase II For AD

This article was originally published in The Pink Sheet Daily

Executive Summary

Antibody works in non-carriers of ApoE4 gene.

You may also be interested in...



Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets

Sources close to the situation say the merged Pfizer/Wyeth entity will probably maintain ongoing Phase III development programs for both dimebon, the Alzheimer's disease medicine Pfizer in-licensed earlier this year, and bapineuzumab, the antibody being tested by Wyeth and Elan. And the reason has as much to do with the much-bandied "shots on goal" strategy as with efficacy signals exhibited so far by either drug

Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets

Sources close to the situation say the merged Pfizer/Wyeth entity will probably maintain ongoing Phase III development programs for both dimebon, the Alzheimer's disease medicine Pfizer in-licensed earlier this year, and bapineuzumab, the antibody being tested by Wyeth and Elan. And the reason has as much to do with the much-bandied "shots on goal" strategy as with efficacy signals exhibited so far by either drug

Whatever Works – Or Might: Pfizer/Wyeth Likely To Keep Both Alzheimer’s Bets

Phase III bapineuzumab could be shaky and same-stage dimebon possibly more solid, but victory with either could spell ‘blockbuster.’

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel